Key result
Long-term hydroxyurea provides sustained efficacy and acceptable safety in young, high-risk essential thrombocythemia patients.
Key points are not available for this paper at this time.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Finazzi et al. (2003) studied this question. Long-term use of hydroxyurea was evaluated for efficacy and safety in young patients with essential thrombocythemia at high risk of thrombohemorrhagic complications.
Synapse has enriched 5 related papers. Consider them for comparative context: